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Abstract 
This study aimed to utilise the value of integrating in 
vitro data and physiologically based pharmacokinetic 
(PBPK) models to quantitatively estimate the impact on 
pharmacokinetics (PK) and pharmacodynamics (PD). The 
objective was to predict pharmacodynamics 
(electrocardiogram (ECG) parameters) of nifedipine 
(NIF) after an oral administration by simulation. The 
computational models were performed for human 
transmural ECGs to model drug-induced changes in QT 
interval as well as changes in T-wave morphology.  
The differences in QTc interval due to NIF in healthy 
volunteers both males and females were predicted by the 
Cardiac Safety Simulator, providing a mechanistic 
understanding of clinical observation. The simulation 
results showed that NIF significantly shortened the QTcF 
in a concentration-dependent manner compared with 
baseline (placebo) control. Comparison of the simulated 
QT interval of non-QT-prolonging drug (NIF) against the 
clinical observations proved the accuracy of the model 
based prediction.  
 
1. Introduction 
This study was designed to evaluate the PD effect of 
NIF on human cardiac myocytes. NIF is a 𝐶𝑎2+ channel 
blocker used in the treatment of various cardiovascular 
diseases, with the pharmacological target in the vascular 
smooth muscles [1]. In the current study, the PK-PD 
models were developed to investigate the PD changes in 
relation to the plasma drug concentrations. Two case 
studies of the PK-PD relation of NIF were analyzed: The 
first simulation study was designed using the drug 
exposure compound file and population data available in 
the Simcyp simulator, and plasma concentration data was 
exported from Simcyp to the Cardiac Safety Simulator 
(CSS) in order to analyse the PK-PD effect of the 
compound at the population level. In the second case a 
clinical study was mimicked [2] by utilizing CSS to 
support in silico assessment. 
 
2. Methods 
Drug pharmacokinetics (PK) was assessed with the use 
of the Simcyp population-based simulator (V15R1 
www.simcyp.com; [3]). The NIF compound file and 
population data [4] available in Simcyp (V15) were used 
for all simulations. NIF is an L-type calcium channel 
blocker used for the treatment of hypertension and angina 
pectoris. To assess the proarrhythmic potency of the drug, 
the Cardiac Safety Simulator (CSS V2.1, Simcyp, 
Sheffield) was used to evaluate pharmacodynamics (the 
cardiac electrophysiological effects) of NIF in a virtual 
human population of European Caucasians 
(NEurCaucasian). The substrate and trial design input 
parameters are presented in Table 1 and 2 respectively. 
Inhibitory activity (i.e. the dose-inhibition relationship) of 
this compound (Table 3) were specified for ion channels 
by using multiple free (unbound) drug concentrations 
expressed in micromoles (μM). The computations were 
performed for human transmural ECGs to model drug-
induced changes in QT interval as well as changes in T-
wave morphology (PD endpoints). The modelling 
approach for this study is described in Figure 1. This 
diagram illustrates the PK-PD relationships (using Simcyp 
and CSS simulators) in which pharmacodynamics examine 
the time course of the biological effects of the drug. The 
mechanism of drug action related to concentration in 
plasma can be predicted using a PBPK modeling approach. 
 
2.1. Model Input Data 
NIF compound (Table 1) was selected for investigation 
for its pure 𝐶𝑎2+ channel blocking properties. The drug 
plasma concentration is taken from the PBPK model and 
utilised as an input to the CSS. The half-maximal 
inhibitory concentration (IC50) and Hill coefficient (h) 
data (Table 3) describing drug triggered ionic current 
modification were used as input parameters in addition to  
multiple free (unbound) drug plasma concentrations (µM).  
 
Table 1. Input parameters (substrate) used in Simcyp 
population-based simulator (V15 R1)  
Substrate 
Compound Name Sim-Nifedipine 
Molecular Weight 
(g/mol) 
346.3 
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log P 2.690 
Compound Type Monoprotic Base 
pKa 2.820 
fu 0.039 
Absorption Model 1st order 
Distribution Model Minimal PBPK Model 
Vss (L/kg) 0.570 
Clearance Type Enzyme Kinetics 
Fasted/Fed Fed 
Route Oral 
Dose Units Dose (mg) 
Dose 10.0 
Start Day/Time Day 1, 09:00 
Dosing Regimen Single Dose 
 
Table 2. Input parameters (trial design) used in Simcyp 
population-based simulator (V15 R1) 
Trial Design 
 
Population Name Sim-Healthy Volunteers 
Population Size 15.00 
Number of Trials 3.00 
No. of Subjects per Trial 5.00 
Start Day/Time Day 1, 09:00 
End Day/Time Day 1, 17:00 
Study Duration (h) 8.00 
Sampling Time Pre-defined Uniform 
 
Table 3. Inhibitory actions of NIF on ion channels in vitro 
Effects of NIF on cardiac transmembrane ion currents  
Ion Channel current 
Inhibitory Potency  
𝐼𝐶50 (µM) 
Inward 
𝐼𝑁𝑎 88.5 (h = 0.71) [5] 
𝐼𝐶𝑎𝐿  0.012 (h = 1.02) [5] 
Outward 
𝐼𝐾𝑟  22
∗ (h = 0.8) [5] 
𝐼𝐾𝑠 360 (h = 0.97) [6] 
* Measured at room temperature and scaled down twofold. 
 
2.2. Human ventricular Cell model and 
Cardiac Safety Simulator (CSS) 
The computational models were derived from the ten 
Tusscher Panfilov 2006 (tT2006) human ventricular model 
[7] by proportionally changing ionic currents based on the 
in vitro measurements. To assess the antiarrhythmic 
potency of the NIF, the CSS platform (V2.1) was used to 
simulate normal (control) signal and drug-induced 
alterations in cardiac AP conduction at the population level 
(i.e. Sim-NEurCaucasian, North European Caucasian) [8].  
 
 
Figure 1. Population-specific simulation schematic 
representation of combination of PK and PD model (using 
Simcyp and CSS simulators). 
 
2.3. Simulation analysis 
The minimal PBPK Model was applied for the PK 
simulations in the Simcyp simulator. The PK model input 
parameters are presented in Tables 1 and 2. The PD effect 
(the electrophysiological characteristics) of NIF was 
conducted in the CSS simulator. The PD end points 
generated in CSS using tT2006 model for this study are: 
AP and ECG morphology, Heart Rate (HR), QTcF (QT 
interval corrected by heart rate using Fridericia correction 
method), Tpeak-Tend, JTpeak, ∆QTcF (difference 
between the average of baseline of all placebo QTcF and 
QTcF in the presence of a drug), ∆Tpeak-Tend and 
∆JTpeak. 
 
3. Results 
3.1. Pharmacokinetic analysis 
The use of mechanistic physiologically based 
pharmacokinetic (PBPK) models allowed the in vivo 
extrapolation of the in vitro parameters and prediction of 
PK parameters. As shown in Figure 2, the systemic 
concentration-time profile of NIF simulated by the 
minimal-PBPK model is used to drive the PD response, 
which is the changes in cardiac electrophysiology 
behaviors such as the QT interval alterations. A summary 
of simulated PK parameters of NIF is presented in Figure 
2. The PK profile showed that the maximum concentration 
was 0.011 µM and occurred at 0.64 h after the dose was 
given. 
Page 2 
  
3.2. Electrophysiological effects (case study 
one) 
In the first case study, the PBPK model was used to 
simulate the PK property of NIF to predict the PD response 
on cardiac electrophysiological characteristics. The effect 
of NIF on the AP of human ventricular epicardial cells and 
ECG waves are shown in Figure 3. NIF shortened the APD 
and QTc intervals in a concentration-dependent manner. A 
very small increase in HR is seen in female population in 
Figure 4. The mechanism of the HR increment with 𝐶𝑎2+ 
channel blockers is not clearly understood, but it could be 
a result of the shortening of the AP and the increase in 
diastolic interval that allows enough time for cells to send 
spontaneous APs more frequently [9]. The obtained QTcF 
simulations results and ΔQTc, ∆Tpeak-Tend and ∆JTpeak 
analysis are presented for both males and females 
separately. The negative slopes for the linear regression of 
ΔQTcF/∆Tpeak-Tend/∆JTpeakc against NIF plasma 
concentrations indicate that the NIF drug shortened QTc 
intervals. A summary of the endpoints 
(electrophysiological parameters) generated on Cardiac 
Safety Simulator at the population level are summarized in 
Tables 4 and 5.  
 
 
 
Figure 2. Simulated mean plasma concentration (µM) time 
profile for 10 mg single dose of NIF in healthy volunteers. 
 
 
 
 
 
 
 
Figure 3. Concentration-dependent effects of NIF on 
cellular AP (left-hand side panels) and 1D ECG (right-
hand side) waveform conducted by using the tT2006 
human (male/female) ventricular cell model. Arrows 
pointing into AP and ECG are showing shortening of the 
repolarization phase. 
 
 
Figure 4. Concentration-dependent effects of NIF on HR 
(blue male, red female) at population level. 
 
Table 4. Endpoints (ECG parameters) generated by the 
CSS for the placebo (base) and the presence of the drug 
(NIF)  
ECG parameters (average value (ms) of all subjects) 
 
QTcF  
(M/F) 
TpeakTend  
(M/F) 
JTpeakc  
(M/F) 
base 423.85/418.51 59.22/59.3 273.8/269.70 
drug 275.1/242.83 46.34/46.3 162.95/135.31 
 
Table 5. The percentage of the variation on the endpoints 
after simulation of different NIF plasma concentrations at 
the population level. 
sex 
*The coefficient of determination of the 
model  𝑅2 (% of the changes 
(reduction)) 
HR 
(b/m) 
∆QTcF ∆TpeakTend ∆JTpeakc 
M 83% 42% 84% 76.64 
F 50% 61% (increased) 69% 74.66 
*CV presented here is the coefficient of variation of the 
Summary Statistics From (h) To (h) TMax (h) CMax (µM) AUC (µM.h)
CuPlasma (µM) 0.00 8.00 0.64 0.011 0.031
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linear regression obtained from the 
ΔQTcF/∆TpeakTend/∆JTpeakc-concentrations plots. 
 
3.3.  Electrophysiological effects (case 
study two) 
The simulation results show that NIF significantly 
shortened the APDs and QTc intervals (Figure 5) in a 
concentration-dependent manner compared with the 
control. The predicted values showed consistency with the 
experimental observations [2] in terms of significant 
reduction of repolarization phase of APD and QTc interval 
length with increasing NIF concentrations that showed the 
degree of the drug’s influence on cardiac repolarization in 
healthy volunteers as compared with the control.  
 
 
 
Figure 5. Left-hand side panel: the representative ECG 
traces of the placebo and with increasing concentrations of 
NIF (data taken from [2]); right-hand side panel: bar graph 
showing changes in ΔQTcF at increasing concentrations of 
NIF. 
 
4. Discussion and conclusions 
We used PK-PD modeling and simulation to describe 
the relationship between individual-predicated plasma 
concentrations and electrophysiological changes in human. 
The PK of the compound was used to obtain time-matched 
plasma concentrations as an input to the CSS to assess 
cardiac electrophysiological drug effect. The first case 
study explored the potential of the PBPK modeling to 
predict the response to the cardiac electrophysiology 
parameters using in vitro data. The study showed the utility 
of PBPK-PD modeling in early cardiac safety screening in 
linking drug concentration at the probable site of action 
with toxicological and/or therapeutic effects.  
The second case study was performed to mimic an 
experimental study (data from human-induced pluripotent 
stem cell-derived cardiomyocytes) [2] to represent an 
assay for predictive electrophysiological safety screening 
using in silico models. The simulation results showed that 
the in silico model was successful in recovering the 
experimental observation [2]. The simulated ΔQTcF 
values proved that a high concentration of NIF (1 μM) 
could inhibit at least 75% of L-type 𝐶𝑎2+ current [10]. In 
our future work, we will investigate the interaction effect 
of a high concentration of NIF (1 μM) that might reduce 
proarrhythmic dose-dependent effects of drugs which 
increase the risk of QT interval prolongation.  
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